Why the study?
Does apixaban provide a safer and more effective alternative to vitamin K antagonists for stroke prevention in dialysis-dependent patients with atrial fibrillation?
Does apixaban provide a safer and more effective alternative to vitamin K antagonists for stroke prevention in dialysis-dependent patients with atrial fibrillation?
This editorial highlights the critical need for alternatives to vitamin K antagonists, such as apixaban, for stroke prevention in dialysis-dependent patients with atrial fibrillation due to the high bleeding risks associated with VKAs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Elaine M. Hylek (2018) conducted an editorial in Atrial fibrillation in patients dependent on dialysis (n=17,380). Vitamin K antagonists (VKAs) vs. No VKAs was evaluated on ischemic stroke (HR 0.74, 95% CI 0.51-1.06, p=nonsignificant).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: